Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

被引：0
|
作者：
Andrew D. Simmons
Minh Nguyen
Elias Pintus
机构：
[1] Translational Medicine,
[2] Clovis Oncology,undefined
[3] Inc.,undefined
[4] Berkshire Cancer Centre,undefined
[5] Royal Berkshire NHS Foundation Trust,undefined
[6] Guy’s Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
BRCA; Prostate cancer; PARP inhibitor; Poly (ADP-ribose) polymerase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The DACH1 gene, frequently co-deleted with BRCA2 in prostate cancer, governs PARP inhibitor resistance
    Li, Zhiping
    Jiao, Xuanmao
    Khan, Taimoor
    Li, Danni
    Zha, Shan
    Phoon, Lai Yee
    Lan, Li
    Robertson, Gordon
    Ashton, Anthony W.
    Iczkowski, Kenneth A.
    Borowsky, Alexander D.
    Ashworth, Alan
    Pestell, Richard G.
    CANCER RESEARCH, 2024, 84 (06)
  • [42] BRCA reversion mutations in circulating cell-free tumour DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma (HGOC)
    Mcneish, I. A.
    Lin, K. K.
    Radke, M. R.
    Oza, A. M.
    Oaknin, A.
    Ray-Coquard, I.
    Tinker, A. V.
    Helman, E.
    Isaacson, J.
    Maloney, L.
    O'malley, D. M.
    Chambers, S. K.
    Kaufmann, S. H.
    Scott, C.
    Konecny, G. E.
    Coleman, R. L.
    Giordano, H.
    Brenton, J. D.
    Harding, T. C.
    Swisher, E. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E28 - E28
  • [43] Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors
    Chen, Hua-Dong
    Guo, Ne
    Song, Shan-Shan
    Chen, Chuan-Huizi
    Miao, Ze-Hong
    He, Jin-Xue
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2813 - +
  • [44] Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report
    Saito, Masayuki
    Fujii, Kimihito
    Banno, Hirona
    Ito, Yukie
    Nakano, Shogo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [45] Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
    Pandya, Deep
    Shah, Myra
    Kaplan, Fuat
    Martino, Candice
    Levy, Gillian
    Kazanjian, Mia
    Batter, Stephen
    Martignetti, John
    Frank, Richard C.
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2021, 7 (01):
  • [46] Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
    Quigley, David
    Alumkal, Joshi J.
    Wyatt, Alexander W.
    Kothari, Vishal
    Foye, Adam
    Lloyd, Paul
    Aggarwal, Rahul
    Kim, Won
    Lu, Eric
    Schwartzman, Jacob
    Beja, Kevin
    Annala, Matti
    Das, Rajdeep
    Diolaiti, Morgan
    Pritchard, Colin
    Thomas, George
    Tomlins, Scott
    Knudsen, Karen
    Lord, Christopher J.
    Ryan, Charles
    Youngren, Jack
    Beer, Tomasz M.
    Ashworth, Alan
    Small, Eric J.
    Feng, Felix Y.
    CANCER DISCOVERY, 2017, 7 (09) : 999 - 1005
  • [47] Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation
    Qing Zhang
    Yaping Li
    Yanrui Zhang
    Zhiping Deng
    Yi Ding
    World Journal of Surgical Oncology, 22
  • [48] Colorectal leiomyosarcoma with BRCA2 mutation benefit from treatment with olaparib: a case report
    Hong, Lei
    Wang, Ya-Nan
    Zhang, Xue
    Zhou, Xinliang
    Fan, Shaoshuang
    Xu, Mian
    Zhang, Shanshan
    Jiang, Da
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1499 - 1504
  • [49] Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation
    Zhang, Qing
    Li, Yaping
    Zhang, Yanrui
    Deng, Zhiping
    Ding, Yi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [50] Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review
    Kryklyva, Valentyna
    Mohammad, Nadia Haj
    Morsink, Folkert H. M.
    Ligtenberg, Marjolijn J. L.
    Offerhaus, G. Johan A.
    Nagtegaal, Iris D.
    de Leng, Wendy W. J.
    Brosens, Lodewijk A. A.
    CANCER BIOLOGY & THERAPY, 2019, 20 (07) : 949 - 955
12345